<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>141(1)</volume><submitter>Groarke EM</submitter><pubmed_abstract>Immune aplastic anemia (AA) is a severe blood disease characterized by T-lymphocyte- mediated stem cell destruction. Hematopoietic stem cell transplantation and immunosuppression are effective, but they entail costs and risks, and are not always successful. The Janus kinase (JAK) 1/2 inhibitor ruxolitinib (RUX) suppresses cytotoxic T-cell activation and inhibits cytokine production in models of graft-versus-host disease. We tested RUX in murine immune AA for potential therapeutic benefit. After infusion of lymph node (LN) cells mismatched at the major histocompatibility complex [C67BL/6 (B6)⇒CByB6F1], RUX, administered as a food additive (Rux-chow), attenuated bone marrow hypoplasia, ameliorated peripheral blood pancytopenia, preserved hematopoietic progenitors, and prevented mortality, wh</pubmed_abstract><journal>Blood</journal><pagination>72-89</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9837431</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Efficacy of JAK1/2 inhibition in murine immune bone marrow failure.</pubmed_title><pmcid>PMC9837431</pmcid><pubmed_authors>Wu Z</pubmed_authors><pubmed_authors>Manley AL</pubmed_authors><pubmed_authors>Chen J</pubmed_authors><pubmed_authors>Feng X</pubmed_authors><pubmed_authors>Groarke EM</pubmed_authors><pubmed_authors>Aggarwal N</pubmed_authors><pubmed_authors>Patel BA</pubmed_authors><pubmed_authors>Young NS</pubmed_authors><pubmed_authors>Gao S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Efficacy of JAK1/2 inhibition in murine immune bone marrow failure.</name><description>Immune aplastic anemia (AA) is a severe blood disease characterized by T-lymphocyte- mediated stem cell destruction. Hematopoietic stem cell transplantation and immunosuppression are effective, but they entail costs and risks, and are not always successful. The Janus kinase (JAK) 1/2 inhibitor ruxolitinib (RUX) suppresses cytotoxic T-cell activation and inhibits cytokine production in models of graft-versus-host disease. We tested RUX in murine immune AA for potential therapeutic benefit. After infusion of lymph node (LN) cells mismatched at the major histocompatibility complex [C67BL/6 (B6)⇒CByB6F1], RUX, administered as a food additive (Rux-chow), attenuated bone marrow hypoplasia, ameliorated peripheral blood pancytopenia, preserved hematopoietic progenitors, and prevented mortality, wh</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-19T19:49:43.056Z</modification><creation>2025-04-19T19:49:43.056Z</creation></dates><accession>S-EPMC9837431</accession><cross_references><pubmed>36130301</pubmed><doi>10.1182/blood.2022015898</doi></cross_references></HashMap>